Entera Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 37
- Market Cap
- $62.4M
- Website
- http://www.enterabio.com
Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Phase 1
Active, not recruiting
- Conditions
- HypoparathyroidismOsteoporosisFractures, BoneOther Disease
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT05965167
- Locations
- 🇮🇱
Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT04003467
- Locations
- 🇮🇱
Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
🇮🇱Hadassah Medical Center, Mt. Scopus Hospital, Jerusalem, Israel
🇮🇱Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism
Phase 2
Completed
- Conditions
- Hypoparathyroidism
- Interventions
- Drug: EB612 (EBP05)Drug: NATPARA/NATPAR
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03516773
- Locations
- 🇮🇱
Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Safety and Bioavailability
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02571140
A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT02202603
- Locations
- 🇮🇱
HMO Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem, Israel
A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism
Phase 2
Completed
- Conditions
- Hypoparathyroidism
- Interventions
- Drug: EnteraBio's Oral Parathyroid Hormone (1-34)
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Entera Bio Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02152228
- Locations
- 🇮🇱
Lin Medical Center, Haifa, Israel
© Copyright 2025. All Rights Reserved by MedPath